Drug Search Results
More Filters [+]

SRT2104

Alternative Names: srt2104
Latest Update: 2023-07-06
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Sirt1 Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Sirtris
Company Location: CAMBRIDGE MA 02139
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for SRT2104

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Type 2 Diabetes|Psoriasis

Phase 1: Type 2 Diabetes|Sepsis|Psoriasis|Muscular Atrophy|Colitis, Ulcerative|Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01453491

P1

Completed

Colitis, Ulcerative

2013-03-18

NCT01702493

P1

Completed

Psoriasis

2012-12-05

NCT01154101

P2

Completed

Psoriasis

2011-11-09

NCT01031108

P1

Completed

Type 2 Diabetes

2011-10-12

Recent News Events